Follow-up Thursday Update On Low Float Nasdaq Profile (BSGM), Trends Green Early
$13.00 Laidlaw & Company Price Target
BSGM is trending green early and this could be a big sign of things to come.
Holding strong above the $4.00 at the moment, strong potential support could be building at that level today.
If that's the case, it could just be a matter of time until this low float idea starts trying to make a push towards yesterday's breakout high of $4.58.
Remember, that was a level that had not been touched in over 2.5 months.
On top of everything, BSGM is trading above multiple lines of potential support (outside of the $4.00 level):
- 20-Day SMA
- 50-Day SMA
- 5-Day EMA
- 13-Day EMA
Drop what you're doing right now to get BSGM on your radar and read my initial report below.
*BioSig Technologies, Inc. (BSGM)*
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Here’s Why PURE EP Could Be a Game-Changer
According to XTalks, PURE EP could fill a significant need because:
“The electrograms used today can be riddled with noise and artifacts coming from other equipment found in the operating room. Such a procedure can take up to six hours, potentially yielding what is referred to in the industry as a ‘dirty signal’ that’s indiscernible to interpret by many electrophysiologists.” (1)
BioSig's PURE EP was developed to address unmet needs in a large and growing market and deliver technology to improve catheter ablation treatments for arrhythmias, Atrial Fibrillation, and Ventricular Tachycardia.
“The system is intended to acquire, digitize, amplify, filter, measure and calculate, display, record and store electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data,” as further reported XTalks. (1)
No. 1 Potential Immediate Term Catalyst - Company's Tech To Be Featured At Stanford Retreat
BioSig’s Signal Processing Technology for Electrophysiology To Be Featured During 2021 Stanford Biodesign New Arrhythmia Technologies Retreat
Westport, CT, June 28, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company would be presenting during 2021 Stanford Biodesign New Arrhythmia Technologies Retreat, due to take place virtually on July 27, 2021. The Company will present at 2 pm PT.
Read the full article here.
No. 2 Potential Immediate Term Catalyst - Potential Squeeze On Horizon?
Check out BSGM's 6-month chart below: